PPARA and metabolic dysfunction-associated steatohepatitis: In contrast to some (e.g., PNPLA3 rs738409) genetically-driven lean NASH patients, ‘metabolically obese’ NASH patients might favor from insulin-sensing PPAR(-(α)/γ) agonists.